Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04500548
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:20.272647+00:00
Published At
2025-09-10T00:00:00+00:00
Record Updated At
2025-09-10
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Constitutional Mismatch Repair Deficiency Syndrome", "Hematopoietic and Lymphoid Cell Neoplasm", "Lynch Syndrome", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Neuroblastoma", "Refractory Primary Central Nervous System Neoplasm", "Xeroderma Pigmentosum"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-10"
protocolSection.identificationModule.nctId
"NCT04500548"
protocolSection.identificationModule.officialTitle
"3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Constitutional Mismatch Repair Deficiency Syndrome (protocolSection.conditionsModule.conditions)
  • Hematopoietic and Lymphoid Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Lynch Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Central Nervous System Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Primary Central Nervous System Neoplasm (protocolSection.conditionsModule.conditions)
  • Xeroderma Pigmentosum (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.